Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Prostatic Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Neoplasms 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Kidney Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 20atezolizumab 8Nivolumab 8Docetaxel 7Carboplatin 6cemiplimab 5Immune Checkpoint Inhibitors 5Radiotherapy 4Paclitaxel 4Filgrastim 4Drug Therapy 4fludarabine 3durvalumab 3Radiosurgery 3Pemetrexed 3Gemcitabine 3Fluorouracil 3Cyclophosphamide 3Cisplatin 3Cetuximab 3Bortezomib 3niraparib 2motexafin gadolinium 2belinostat 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2aldesleukin 2Tobacco Use Cessation Devices 2Tetrahydrouridine 2Taxes 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Solutions × Genitourinary × Clear all
NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡